Yelena Birger, MD
Internal Medicine · Jamaica, NYNPI 1376598136
Payments from drug & device makers
Across 336 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$749
- Johnson & Johnson$460
- Amarin Pharma, Inc.$248
- GSK$241
- Amgen$228
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,845100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $1,316 |
| AstraZeneca | 50 | $749 |
| Johnson & Johnson | 34 | $460 |
| Amarin Pharma, Inc. | 20 | $248 |
| GSK | 18 | $241 |
| Amgen | 15 | $228 |
| Boehringer Ingelheim | 15 | $197 |
| Nestle Healthcare Nutrition Inc. | 11 | $165 |
| Lilly USA, LLC | 10 | $140 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $137 |
| Phathom Pharmaceuticals, Inc. | 8 | $114 |
| Aimmune Therapeutics, Inc. | 6 | $101 |
| Ironwood Pharmaceuticals, Inc | 7 | $101 |
| Zimmer Biomet | 1 | $86 |
| Novo Nordisk | 4 | $78 |
| Bayer | 3 | $64 |
| Scilex Pharmaceuticals Inc. | 4 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $55 |
| Astellas Pharma US Inc | 3 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Pfizer | 2 | $30 |
| Novartis | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Merck | 2 | $24 |
| Exact Sciences | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,854 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 203 | $149,434 |
| LinzessLinaclotide | 254 | $146,033 |
| OzempicSemaglutide | 139 | $138,836 |
| EliquisApixaban | 163 | $111,775 |
| CreonLipase/Protease/Amylase | 79 | $104,147 |
| Diclofenac Sodium | 306 | $101,633 |
| ProliaDenosumab | 56 | $92,025 |
| VascepaIcosapent Ethyl | 251 | $89,694 |
| FarxigaDapagliflozin Propanediol | 113 | $88,897 |
| TradjentaLinagliptin | 125 | $86,210 |
| MounjaroTirzepatide | 67 | $73,567 |
| XareltoRivaroxaban | 83 | $55,552 |
| JanuviaSitagliptin Phosphate | 68 | $53,376 |
| TrulicityDulaglutide | 45 | $47,283 |
| ZegeridOmeprazole/Sodium Bicarbonate | 13 | $44,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Ubrelvy, Restasis Multidose, Restasis | $1,316 | $284,721372 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $197 | $243,892342 claims |
| Novo NordiskOzempic | $78 | $138,836139 claims |
| Lilly USA, LLCMounjaro, Trulicity | $140 | $120,851112 claims |
| PfizerEliquis | $30 | $111,775163 claims |
| AstraZenecaFarxiga, Nexium | $749 | $97,298146 claims |
| AmgenProlia | $228 | $92,02556 claims |
| MerckJanuvia, Janumet | $24 | $90,189138 claims |
| Johnson & JohnsonXarelto | $460 | $55,55283 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCZegerid | $137 | $44,96513 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $14 | $32,08662 claims |
| Aimmune Therapeutics, Inc.Zenpep | $101 | $27,38429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Jamaica
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.